Leerink Partners analyst Michael Schmidt raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $36.00 (from $26.00) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Ionis Pharmaceuticals (IONS) PT Raised to $40 at BMO CapitalAugust 1, 2016 12:22 PM Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for EfficacyAugust 1, 2016 12:20 PM Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMAAugust 1, 2016 7:34 AM Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular AtrophyAugust 1, 2016 7:30 AM Ionis Pharma (IONS) Unit Receives EC Orphan Drug Designation Volanesorsen as FPL TreatmentJuly 28, 2016 4:01 PM